ORganoid GeneratioN Study for Cancer

Cancer Clinical Trial

— ORIGINS  

Official title:

ORganoid GeneratioN Study for Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05734963
• Other study ID #: CCR5396
• Status: Recruiting
• Start date: April 4, 2022
• Est. completion date: April 12, 2031

Study information

• Verified date: May 2024
• Source: Royal Marsden NHS Foundation Trust
• Contact: Ben O'Leary
• Phone: 02071535337
• Email: ben.oleary[@]icr.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

ORIGINS - a multi-site sample collection study to establish patient-derived pre-clinical models for cancers

Description:

People who develop cancer can often be cured if they are suitable for surgery or radiotherapy. However, a proportion of these cancers return, at which point the available treatment options are often not very effective. Our understanding of the biology of many cancers is limited, and we don't understand why some cancers are cured by surgery or radiotherapy and some are not. A better understanding of the biology of cancers could help develop new treatments, or improvements to current treatments, and this might increase the number of patients who can be cured of their disease.

One way to improve the understanding we have of the biology is to look in detail at cancer samples taken from the from patients. The problem with this is that often samples are small, and the tumour tissue sample itself already dead once removed from where it was growing, which can limit the analyses that are possible. A potential solution for this is to take cancer tissue from patients and try to directly grow the cells in the laboratory. Keeping the cancer cells alive in the laboratory can be difficult but has been shown to be possible in a number of different types of cancer. This kind of model is sometimes known as an "organoid". If successfully established, it means more tests can be done to find out how the cancer is working.

This study is looking at collecting samples of a person's cancer to see if we can develop these models from patients being treated for different cancers. We will ask people who are having surgery for cancer whether we can take samples from their tumour to try and achieve this. Some additional blood tests will be taken alongside the usual blood tests before and after surgery, without an additional blood draw, and before and again after any adjuvant therapy is completed. A collection of saliva will also be requested at these times and we will ask people whether they are happy for us to collect any previous tissue samples, or nay that are subsequently collected when they are being followed up, to allow comparison with the samples collected as part of this study.

The main goal of this study is to see if organoids can be established in our laboratories. If these models are successfully established, we will compare them to the original tumour to check they are a good match biologically. After this we can use them to understand how the cancer works and try out new treatments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: April 12, 2031
• Est. primary completion date: April 12, 2031
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older

• Patients with histologically proven or suspected cancer undergoing an interventional procedure, such as surgery or biopsy

• Ability to give informed consent for biological sample collection

Exclusion Criteria:

• Unable to undergo sample collection

• Pregnancy

Related Conditions & MeSH terms

• Cancer

Intervention

Genetic:
• DNA sequencing, RNA gene expression analysis, molecular profiling
Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling

Locations

Country	Name	City	State
United Kingdom	The Royal Marsden Hospital	London

Sponsors (1)

Lead Sponsor	Collaborator
Royal Marsden NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establish patient-derived organoid (PDO) model for cancers	Establish patient-derived organoid (PDO) model for cancers	Time Frame: Through study completion, expected duration of 9 years
Secondary	To collection contemporaneous biological samples from patients with cancer before and after surgery/biopsy, and again after any adjuvant therapy	To collection contemporaneous biological samples from patients with cancer before and after surgery/biopsy, and again after any adjuvant therapy - including blood, saliva and tissue, for molecular profiling, including extraction of DNA for sequencing, RNA	Time Frame: Through study completion, expected duration of 9 years
Secondary	To collect tumour tissue to facilitate evolutionary analysis with molecular analysis of multiple regions	To collect tumour tissue to facilitate evolutionary analysis with molecular analysis of multiple regions	Time Frame: Through study completion, expected duration of 9 years
Secondary	Retrieval and analysis of archival primary tissue blocks for comparison where available	Retrieval and analysis of archival primary tissue blocks for comparison where available	Time Frame: Through study completion, expected duration of 9 years
Secondary	To establish co-culture tumour/stroma/immune cell models	To establish co-culture tumour/stroma/immune cell models	Time Frame: Through study completion, expected duration of 9 years
Secondary	To observe associations between molecular and clinicopathological data	To observe associations between molecular and clinicopathological data	Time Frame: Through study completion, expected duration of 9 years